Why Is Nuvation Bio Stock Gaining Monday? - Nuvation Bio (NYSE:NUVB)

Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.

Raccontata dabenzinga.com